Richard Heyman, PhD

Richard A. Heyman, PhD, is a scientist and entrepreneur with more than 25 years of experience in co-founding and building biotech companies. Rich most recently served as Chairman of Vividion Therapeutic and Amunix Pharma, both independently purchased in 2021. He is the co-founder and Chairman of ORIC Pharmaceuticals, which is developing drugs for oncology. Previously, Rich was the co-founder and CEO of Aragon and Seragon Pharmaceuticals, which focused on therapeutics targeting hormone dependent cancers. He has been involved in the discovery and development of multiple therapeutic agents approved by the FDA, including the prostate cancer drug, Erleada. In addition to his corporate experience, Rich is Vice Chair of the Board of Trustees at the Salk Institute, the BOD at UC San Diego Moores Cancer Center and a founding member of both Life Science Cares, San Diego and Curebound.

He has won numerous awards including Ernst and Young San Diego Regional Entrepreneur of the Year, Connect Hall of Fame Award and the Endocrine Society Outstanding Innovation Award. Earlier in his career he trained as an NIH postdoctoral fellow and staff scientist at the Salk Institute. Rich is the author or inventor on more than 125 publications and patents